Chemical Structure (Ganciclovir 1)
Chemical structure of Ganciclovir, showing its molecular composition and arrangement of atoms.*
Ganciclovir Injection, Powder, Lyophilized, For Solution
Product Images NDC 42023-173
6 FDA label images from Par Health Usa, Llc · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ganciclovir (NDC 42023-173). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Par Health Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Ganciclovir 2)
Chemical structure diagram of ganciclovir showing its molecular arrangement with various functional groups, consistent with the active ingredient ganciclovir in the injection powder product.*
Figure 1 (Ganciclovir 3)
A line graph titled 'ICM 1653: Time to Progression of CMV Retinitis' comparing the proportion without progression over time for IV and oral routes. The x-axis shows days from start of maintenance therapy (0 to 150), and the y-axis shows proportion without progression (0 to 1). Two lines represent intravenous (dashed) and oral (solid) administration, both decreasing over time.*
Figure 2 (Ganciclovir 4)
A Kaplan-Meier survival curve titled 'ICM 1774: Time to Progression of CMV Retinitis,' comparing intravenous (IV) and oral administration routes. The Y-axis shows the proportion without progression, ranging from 0 to 1, and the X-axis shows time from start of maintenance therapy in days, up to 120. The dashed line represents IV administration, and the solid line represents oral administration, illustrating different rates of progression over time.*
Figure 3 (Ganciclovir 5)
A line graph titled "AVI 034: Time to Progression of CMV Retinitis" showing the proportion of patients without progression over time from the start of maintenance therapy in days. Two lines compare intravenous (IV) and oral administration routes, with the proportion decreasing over approximately 150 days for both.*
Ph Carton (Ganciclovir 6)
Packaging label for Ganciclovir for Injection, USP, 500 mg/vial, lyophilized powder for intravenous infusion. The label indicates the product is for prescription use only, contains 25 single-dose vials of 500 mg each, and includes a caution that it is a cytotoxic agent. It is manufactured by Par Health USA, LLC.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
